Klotho as a potential biomarker and therapy for acute kidney injury

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

Klotho is a single-pass transmembrane protein that is highly expressed in the kidney and is known to act as a coreceptor for fibroblast growth factor 23. The extracellular domain can be produced independently or shed from membrane-bound Klotho and functions as an endocrine substance with multiple functions including antioxidation, modulation of ion transport, suppression of fibrosis, and preservation of stem cells. Emerging evidence has revealed that Klotho deficiency is an early event in acute kidney injury (AKI), and a pathogenic factor that exacerbates acute kidney damage and contributes to long-term consequences. Restoration by exogenous supplementation or stimulation of endogenous Klotho might prevent and ameliorate injury, promote recovery, and suppress fibrosis to mitigate development of chronic kidney disease. Although data are still emerging, in this Perspectives article we discuss why this renal-derived protein is a highly promising candidate as both an early biomarker and therapeutic agent for AKI.

Original languageEnglish (US)
Pages (from-to)423-429
Number of pages7
JournalNature Reviews Nephrology
Volume8
Issue number7
DOIs
StatePublished - Jul 2012

Fingerprint

Acute Kidney Injury
Biomarkers
Kidney
Fibrosis
Ion Transport
Chronic Renal Insufficiency
Proteins
Stem Cells
Therapeutics
Membranes
Wounds and Injuries

ASJC Scopus subject areas

  • Nephrology

Cite this

Klotho as a potential biomarker and therapy for acute kidney injury. / Hu, Ming C; Moe, Orson W.

In: Nature Reviews Nephrology, Vol. 8, No. 7, 07.2012, p. 423-429.

Research output: Contribution to journalArticle

@article{23abf0cd823344e588ed6f585ff4d496,
title = "Klotho as a potential biomarker and therapy for acute kidney injury",
abstract = "Klotho is a single-pass transmembrane protein that is highly expressed in the kidney and is known to act as a coreceptor for fibroblast growth factor 23. The extracellular domain can be produced independently or shed from membrane-bound Klotho and functions as an endocrine substance with multiple functions including antioxidation, modulation of ion transport, suppression of fibrosis, and preservation of stem cells. Emerging evidence has revealed that Klotho deficiency is an early event in acute kidney injury (AKI), and a pathogenic factor that exacerbates acute kidney damage and contributes to long-term consequences. Restoration by exogenous supplementation or stimulation of endogenous Klotho might prevent and ameliorate injury, promote recovery, and suppress fibrosis to mitigate development of chronic kidney disease. Although data are still emerging, in this Perspectives article we discuss why this renal-derived protein is a highly promising candidate as both an early biomarker and therapeutic agent for AKI.",
author = "Hu, {Ming C} and Moe, {Orson W}",
year = "2012",
month = "7",
doi = "10.1038/nrneph.2012.92",
language = "English (US)",
volume = "8",
pages = "423--429",
journal = "Nature Reviews Nephrology",
issn = "1759-507X",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Klotho as a potential biomarker and therapy for acute kidney injury

AU - Hu, Ming C

AU - Moe, Orson W

PY - 2012/7

Y1 - 2012/7

N2 - Klotho is a single-pass transmembrane protein that is highly expressed in the kidney and is known to act as a coreceptor for fibroblast growth factor 23. The extracellular domain can be produced independently or shed from membrane-bound Klotho and functions as an endocrine substance with multiple functions including antioxidation, modulation of ion transport, suppression of fibrosis, and preservation of stem cells. Emerging evidence has revealed that Klotho deficiency is an early event in acute kidney injury (AKI), and a pathogenic factor that exacerbates acute kidney damage and contributes to long-term consequences. Restoration by exogenous supplementation or stimulation of endogenous Klotho might prevent and ameliorate injury, promote recovery, and suppress fibrosis to mitigate development of chronic kidney disease. Although data are still emerging, in this Perspectives article we discuss why this renal-derived protein is a highly promising candidate as both an early biomarker and therapeutic agent for AKI.

AB - Klotho is a single-pass transmembrane protein that is highly expressed in the kidney and is known to act as a coreceptor for fibroblast growth factor 23. The extracellular domain can be produced independently or shed from membrane-bound Klotho and functions as an endocrine substance with multiple functions including antioxidation, modulation of ion transport, suppression of fibrosis, and preservation of stem cells. Emerging evidence has revealed that Klotho deficiency is an early event in acute kidney injury (AKI), and a pathogenic factor that exacerbates acute kidney damage and contributes to long-term consequences. Restoration by exogenous supplementation or stimulation of endogenous Klotho might prevent and ameliorate injury, promote recovery, and suppress fibrosis to mitigate development of chronic kidney disease. Although data are still emerging, in this Perspectives article we discuss why this renal-derived protein is a highly promising candidate as both an early biomarker and therapeutic agent for AKI.

UR - http://www.scopus.com/inward/record.url?scp=84862840249&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862840249&partnerID=8YFLogxK

U2 - 10.1038/nrneph.2012.92

DO - 10.1038/nrneph.2012.92

M3 - Article

C2 - 22664739

AN - SCOPUS:84862840249

VL - 8

SP - 423

EP - 429

JO - Nature Reviews Nephrology

JF - Nature Reviews Nephrology

SN - 1759-507X

IS - 7

ER -